Alcoholic Liver Disease

Part of the Molecular Pathology Library book series (MPLB, volume 5)


Alcoholic liver disease (ALD) remains a significant health burden in the USA and worldwide. The histological spectrum of this disease spans from simple steatosis to steatohepatitis (characterized by inflammatory cell infiltration, hepatocyte ballooning, apoptosis, and necrosis in addition to fat accumulation) to fibrosis and overt cirrhosis. Steatosis in this setting is mainly macrovesicular and most prominent in the centrilobular region or zone 3. Early stages of alcohol-induced liver injury are reversible and prevention of steatosis in experimental models has been shown to prevent progression to inflammation and fibrosis.


Fatty Liver Stellate Cell Alcoholic Liver Disease Chronic Ethanol Alcoholic Hepatitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    French SW, Nash J, Shitabata P, et al. Pathology of alcoholic liver disease. Semin Liver Dis. 1993;13:154–69.PubMedGoogle Scholar
  2. 2.
    Zakhari S, Li T-K. Determinants of alcohol use and abuse: impact of quality and frequency patterns on liver disease. Hepatology. 2007;46:2032–9.PubMedGoogle Scholar
  3. 3.
    Crews FT. Summary report of a symposium: genes and genes delivery for diseases of alcoholism. Alcohol Clin Exp Res. 2001;25:1778–800.PubMedGoogle Scholar
  4. 4.
    Nanji AA, Su GL, Laposata M, et al. Pathogenesis of alcoholic liver disease-recent advances. Alcohol Clin Exp Res. 2002;26:731–6.PubMedGoogle Scholar
  5. 5.
    Li J, Nguyen V, French BA, et al. Mechanism of the cyclic pattern of urinary ethanol levels in rats fed ethanol. The role of the hypothalamic-pituitary-thyroid axis. Am J Physiol. 2000;279:G118–25.Google Scholar
  6. 6.
    Bardag-Gorce F, French BA, Li J, et al. The importance of cycling of blood alcohol levels in the pathogenesis of experimental alcoholic liver disease in rats fed ethanol intragastrically. Gastroenterology. 2002;123:325–35.PubMedGoogle Scholar
  7. 7.
    Li J, French B, Wu Y, et al. Liver hypoxia and lack of recovery after reperfusion at high blood alcohol levels in the intragastric feeding model of alcohol liver disease. Exp Mol Pathol. 2004;77:184–92.PubMedGoogle Scholar
  8. 8.
    Seth D, Leo MA, McGuinness PH, et al. Gene expression profiling of alcoholic liver disease in the baboon (Papiohamadryas) and human liver. Am J Pathol. 2003;163:2303–17.PubMedGoogle Scholar
  9. 9.
    Seth D, Gorrell MD, McGuinness PH, et al. SMART amplification maintains representation of relative gene expressions quantitative validation by real time PCR and application to studies of alcoholic liver disease in primates. J Biochem Bioiphys Methods. 2003;55:53–66.Google Scholar
  10. 10.
    Deaciuc IV, Arteel GE, Peng X, et al. Gene expression in the liver of rats fed alcohol by means of intragastric infusion. Alcohol. 2004;33:17–30.PubMedGoogle Scholar
  11. 11.
    Bardag-Gorce F, Oliva J, Dedes J, et al. Chronic ethanol feeding alters hepatocyte memory which is not altered by acute feeding. Alcohol Clin Exp Res. 2009;33:684–92.PubMedGoogle Scholar
  12. 12.
    Deaciuc IV, Doherty DE, Burickhanov R, et al. Large-scale gene profiling of the liver in a mouse model of chronic intragastric ethanol infusion. J Hepatol. 2004;40:219–27.PubMedGoogle Scholar
  13. 13.
    Tadic SD, Elm MS, Li H-S, et al. Sex differences in hepatic gene expression in a rat model of ethanol-induced liver injury. J Appl Physiol. 2002;93:1057–68.PubMedGoogle Scholar
  14. 14.
    Ji C, Kaplowitz Α (ALPHA). Betaine decreases hyperchromocysteinemia, endoplasmic reticulum stress and liver injury in alcohol fed mice. Gastroenterology 2003, 124:1488–1499.Google Scholar
  15. 15.
    Deaciuc IV, Song Z, McCain CJ. Lessons from large-scale gene profiling of the liver in alcoholic liver disease. Hepatol Res. 2005;31:187–92.PubMedGoogle Scholar
  16. 16.
    French BA, Dedes J, Bardag-Gorce F, et al. Microarray analysis of gene expression of the liver during urinary ethanol cycle in rats fed ethanol intragastrically at a constant rate. Exp Mol Pathol. 2005;79:87–94.PubMedGoogle Scholar
  17. 17.
    Bardag-Gorce F, French BA, Nan L, et al. CYP2E1 induced by ethanol causes oxidative stress, proteasome inhibition and cytokeratin aggresome (Mallory body-like) formation. Exp Mol Pathol. 2006;81:191–201.PubMedGoogle Scholar
  18. 18.
    Bardag-Gorce F, Yuan QX, Li J, et al. The effect of ethanol-induced cytochrome P450 2E1 on the inhibition of proteasome activity by alcohol. BBRC. 2000;279:23–9.PubMedGoogle Scholar
  19. 19.
    Oliva J, Dedes J, Li J, et al. Epigenetics of proteasome inhibition in the liver of rats fed ethanol chronically. World J Gastroenterol. 2009;15:705–12.PubMedGoogle Scholar
  20. 20.
    Butra A, Ingelman-Sundberg M, Morgan K, et al. The impact of CYP2E1 on the development of alcoholic liver disease as studied in a transgenic mouse model. J Hepatol. 2009;50:572–83.Google Scholar
  21. 21.
    Li J, Bardag-Gorce F, Oliva J, et al. Gene expression modification in the liver caused by binge and S-adenosylmethionine feeding. The role of epigenetic changes. Genes Nutr. 2009; (accepted).Google Scholar
  22. 22.
    Park PH, Miller R, Shukla SD. Acetylation of histone H3 at lysine 9 by ethanol on rat hepatocytes. Biochem Biophys Res Commun. 2003;306:501–4.PubMedGoogle Scholar
  23. 23.
    Park PH, Lim RW, Shukla SD. Involvement of histone acetylation (AAT) in ethanol-induced acetylation of histone H3 is hepatocytes potential mechanism for gene expression. Am J Physiol Gastrointest Liver Physiol. 2005;289:1124–36.Google Scholar
  24. 24.
    Rogers JT. L erin C, Gerhart-Hines Z, et al. Molecular adaptions through the PGC-1 alpha and Sirt1 pathways. FEBS Lett. 2008;582:46–53.Google Scholar
  25. 25.
    Oliva J, French BA, Li J, et al. Sirt is involved in energy metabolism: the role of chronic ethanol feeding and resveratrol. Exp Mol Pathol. 2008;85:155–9. Erratum (published).PubMedGoogle Scholar
  26. 26.
    Pat-Bhadra M, Bhadra V, Jackson DJ, et al. Distinct methylation patterns in histone H3 at lys-4 and lys-5 correlated with up-and down regulation of genes by ethanol in hepatocytes. Life Sci. 2007;81:979–87.Google Scholar
  27. 27.
    Lee YJ, Shukla SD. Histone H3 phoshorylation at serine 10 and serine 28 is mediated by p38 MAPK in rat hepatocytes exposed to ethanol and acetaldehyde. Eur J Pharmacol. 2007;573:29–38.PubMedGoogle Scholar
  28. 28.
    Bardag-Gorce F, French BA, Dedes J, et al. Gene expression patterns of the liver in response to alcohol: in vivo and in vitro models compared. Exp Molec Pathol. 2006;80:241–51.Google Scholar
  29. 29.
    Seth D, Correll MD, Cordoba S, et al. Intrahepatic gene expression in human alcoholic hepatitis. J Hepatol. 2006;45:306–20.PubMedGoogle Scholar
  30. 30.
    Janvelainen HA, Fang C, Ingelman-Sundberg M. Effect of chronic co-administration of endoxin and ethanol on rat liver pathology and pro-inflammatory and anti-inflammatory cytokines. Hepatology. 1999;29:1503–10.Google Scholar
  31. 31.
    Shukla SD, Velzquez J, French SW, et al. Emerging role of epigenetics in the actions of alcohol. Alcohol Clin Exp Res. 2008;32:1–10.Google Scholar
  32. 32.
    Colmenero J, Bataller R, Sancho-Bru P, et al. Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity. Gastroenterology. 2007;132:687–97.PubMedGoogle Scholar
  33. 33.
    Zima T, Kalousova M. Oxidative stress and signal transduction pathways in alcoholic liver disease. Alcohol Clin Exp Res. 2005;29:110S–5.PubMedGoogle Scholar
  34. 34.
    Mezey E, Potter JJ, Rannie-Tankersely L, Caballera J, Pares A. A randomized placebo controlled trial of vitam E for alcoholic hepatitis. J Hepatol. 2004;40:40–6.PubMedGoogle Scholar
  35. 35.
    Jaruga B, Hong F, Kim W-H, et al. Chronic alcohol consumption accelerates liver injury in T cell-mediated hepatitis: alcohol disregulation of NF-KB and STAT3 signaling pathway. Am J Physiol Gastrointest Liver Physiol. 2004;287:G471–9.PubMedGoogle Scholar
  36. 36.
    Hirtz I, Mandrekar P, Velyudham A, et al. The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88. Hepatology. 2008;48:1224–31.Google Scholar
  37. 37.
    French SW. Alcoholic hepatitis: Inflammatory cell mediated hepatocellular injury. Alcohol. 2002;26:43–6.Google Scholar
  38. 38.
    Seth D, Gorrell MD, Cordoba S, et al. Intrahepatic gene expression in human alcoholic hepatitis. J Hepatol. 2006;45:306–20.PubMedGoogle Scholar
  39. 39.
    Banerjee A, Lee J-H, Ramaiah SK. Interaction of osteopontin with neutrophil a4B1 and AqB1 integrins in a rodent model of alcoholic liver disease. Toxicol Appl Pharmacol. 2008;233:238–46.PubMedGoogle Scholar
  40. 40.
    Ramaian SK, Jaeschke H. Hepatic neutrophil infiltration in the pathogenesis of alcohol-induced liver injury. Toxicol Mech Methods. 2007;17:431–40.Google Scholar
  41. 41.
    Prichard MT, Nagy LE. Ethanol-induced liver injury: potential roles for Egr-1. Alcoholism Clin Exp Res. 2005;29:146S–50.Google Scholar
  42. 42.
    Tsuji Y, Kumashiro R, Ishii K, et al. Severe alcoholic hepatitis successfully treated by leukocytapheresis: a case report. Alcohol Clin Exp Res. 2003;27:26s–31.PubMedGoogle Scholar
  43. 43.
    Wang MX, Morgan T, Lungo W, et al. “Piecemeal” necrosis: renamed troxis necrosis. Exp Mol Pathol. 2001;71:137–46.PubMedGoogle Scholar
  44. 44.
    Albano E, French SW, Ingelman-Sundberg M. Hydroxyethyl radicals in ethanol hepatotoxicity. Front Biosci. 1999;4:D533–40.PubMedGoogle Scholar
  45. 45.
    Minagawa M, Deng Q, Liu Z-X, et al. Activated natural killer T cells induce liver injury by Fas and tumor necrosis factor-α(alpha) during alcohol consumption. Gastroenterology. 2004;126:1387–99.PubMedGoogle Scholar
  46. 46.
    Tagami A, Ohmshi H, Moriwaki H, et al. Fas-mediated apoptosis in acute alcoholic hepatitis. Hepato-Gastroenterol. 2003;50:443–8.Google Scholar
  47. 47.
    Fernandez-Checa JC, Colell A, Mari M, et al. Ceramide, tumor necrosis factor and alcohol-induced liver disease. Alcohol Clin Exp Res. 2005;29:1515–75.Google Scholar
  48. 48.
    Kaplowitz Α (ALPHA), Ji C. Unfolding new mechanisms of alcoholic liver disease in the endoplasmic reticulum. J Gastroenterol Hepatol. 2006;21:57–9.Google Scholar
  49. 49.
    Bleich S, Lenz B, Ziegenbein M, et al. Epigenetic DNA hypermethylation of the HERP gene promoter induces down regulation of its mRNA expression in patients with alcohol dependance. Alcohol Clin Exp Res. 2006;30:587–91.PubMedGoogle Scholar
  50. 50.
    Purohit V, Gao B, Song B-J. Molecular mechanisms of alcohol fatty liver. Alcohol Clin Exp Res. 2009;33:191–205.PubMedGoogle Scholar
  51. 51.
    You M, Matsumoto M, Pacold CM, et al. The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology. 2004;127:1798–808.PubMedGoogle Scholar
  52. 52.
    Esfandiari F, You M, Villanueva JA, et al. S-adenosylmethione (SAM) attenuates hepatic lipid synthesis in micropigs fed ethanol with a folate deficient diet. Alcohol Clin Exp Res. 2007;31:1231–9.PubMedGoogle Scholar
  53. 53.
    Chen X, Sebastian BM, Tang H, et al. Taurine supplement at non prevents ethanol-induced disease in serum adiponectin and reduces hepatic steatosis in rats. Hepatology. 2009;49:1554–62.PubMedGoogle Scholar
  54. 54.
    Xu A, Wang Y, Keshaw H, et al. The fat derived hormone adiponectin attenuates alcoholic and nonalcoholic fatty liver disease in mice. J Clin Invest. 2003;112:91–100.PubMedGoogle Scholar
  55. 55.
    Endo M, Masaki T, Seike M, et al. TNF-α(alpha) induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binching protein-1c (SREBP-1c). Exp Biol Med. 2007;232:614–21.Google Scholar
  56. 56.
    Sierksma A, Patel H. Ouchi Α(ALPHA), et al. Effect of moderate alcohol consumption on adiponectin tumor necrosis factor-α(alpha) and insulin sensitivity. Diabetes Care. 2004;27:184–9.PubMedGoogle Scholar
  57. 57.
    Ouchi Α (ALPHA), Kihara S, Arta Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-KB signaling through a cAMP-dependent pathway. Circulation 2000; 10Z:1296–301.Google Scholar
  58. 58.
    Yamauchi T, Kamon J, Waki H, et al. Global adiponectin protected ob/ob mice from diabetes and APOE–deficient mice from atherosclerosis. J Biol Chem. 2003;278:2461–8.PubMedGoogle Scholar
  59. 59.
    Rogers CQ, Ajmo JM, You M. Adiponectin and alcohlic fatty liver disease. UBMD Life. 2008;60:790–7.Google Scholar
  60. 60.
    Wan Y-J, Morimoto M, Thurman RG, et al. Expression of peroxisome proliferator-activated receptor gene is decreased in experimental alcoholic liver disease. Life Sciences. 1995;56:307–17.PubMedGoogle Scholar
  61. 61.
    Nanji AA, Dannenberg AJ, Jokelainen K, et al. Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-alpha (PPAR-alpha)-regulated genes and is ameliorated by PPAR alpha activation. J Pharmacol Exp Ther. 2004;310:417–24.PubMedGoogle Scholar
  62. 62.
    El-Assal O, Hong F, Kim WH, et al. IL-6 protects against ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver. Cell Mol Immunol. 2004;1:205–11.PubMedGoogle Scholar
  63. 63.
    Horiguchi Α (ALPHA), Wang L, Mukhopadhyay P, et al. Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. Gastroenterology 2008;134:1148–58.Google Scholar
  64. 64.
    Ronis MJJ, Butura A, Korourian S, et al. Cytokine and chemokine expression associated with steatohepatitis and hepatocyte proliferation in rats fed ethanol via total enteral mutation. Exp Biol Med. 2008;233:344–56.Google Scholar
  65. 65.
    Prichard MT, McMullen MR, Stavinsky AB, et al. Differential contributions of C3, C5 and decay-accellerating factor to ethanol-induced fatty liver in mice. Gastroenterology. 2007;137:1117–25.Google Scholar
  66. 66.
    Bykov J, Jauhiainem M, Olkonen VM, et al. Hepatic gene expression and lipid parameters in complement C3 (-/-) mice that do not develop ethanol-induced steatosis. J Hepatol. 2007;46:907–14.PubMedGoogle Scholar
  67. 67.
    Jeong WI, Osci-Hyiaman D, Park O, et al. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell-Metab. 2008;7:227–35.PubMedGoogle Scholar
  68. 68.
    Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrate in health and disease. Physiol Rev. 2007;87:315–424.PubMedGoogle Scholar
  69. 69.
    Vankatraman A, Landar A, Davis AJ, et al. Oxidative modifications of hepatic mitochondria protein thiols: effects of chronic alcohol consumption. Am J Physiol Gastrointest Liver Physiol. 2004;286:G521–7.Google Scholar
  70. 70.
    Bardag-Gorce F, Li J, French BA, et al. The effect of ethanol-induced CYP2E1 on proteasome activity: The role of 4-hydroxynonenal. Exp Mol Pathol. 2005;78:109–15.PubMedGoogle Scholar
  71. 71.
    Bardag-Gorce F, Venkatesh R, Li J, et al. Hypersphosphorylation of rat liver proteasome subunits: the effects of ethanol and okadaic acid compared. Life Sci. 2004;75:585–97.PubMedGoogle Scholar
  72. 72.
    French SW, Benson NC, Sun PS. Centrilobular liver necrosis induced by hypoxia in chronic ethanol-fed rats. Hepatology. 1984;4:912–7.PubMedGoogle Scholar
  73. 73.
    Gouillon ZQ, Miyamoto K, Donohue TM, et al. Role of CYP2E1 in the pathogenesis of alcoholic liver disease: Modifications by cAMP and ubiquitin-proteasome pathway. Frontiers of Bioscience. 1999;4:16–25.Google Scholar
  74. 74.
    Bardag-Gorce F, Francis T, Nan L, et al. Modifications in p62 occur due to proteasome inhibition in alcoholic liver disease. Life Sci. 2005;77:2594–602.PubMedGoogle Scholar
  75. 75.
    Zhang-Gouillon ZQ, Yuan QX, Hu B, et al. Alcohol induces Mallory body formation in drug primed mice. Hepatology. 1998;27:116–22.PubMedGoogle Scholar
  76. 76.
    Bardag-Gorce F, French BA, Lue YH, et al. Mallory body formation in proteasome-depleted hepatocytes: an immunohistochemical study. Exp Molec Pathol. 2001;70:7–18.Google Scholar
  77. 77.
    Riley NE, Li J, Worrall S, et al. The Mallory body as an aggresome: In vitro studies. Exp Molec Pathol. 2002;72:17–23.Google Scholar
  78. 78.
    Riley NE, Bardag-Gorce F, Montgomery RO, et al. Microtubules are required for cytokeratin aggresome formation in hepatocytes (Mallory bodies) an in vitro study. Exp Molec Pathol. 2003;74:173–9.Google Scholar
  79. 79.
    Zatloukal K, French SW, Stumpter C, et al. From Mallory Denk inclusion bodies: what, how and why? Exp Cell Res. 2007;313:2033–40.PubMedGoogle Scholar
  80. 80.
    Ohta M, Marceau N, Perry G, et al. Ubiquitin is present on the cytokeratin intermediate filaments and Mallory bodies of hepatocytes. Lab Invest. 1988;58:848–56.Google Scholar
  81. 81.
    McPhaul LW, Wang J, Hol EM, et al. Molecular misreading of the ubiquitin B gene and hepatic Mallory body formation. Gastroenterology. 2002;122:1878–85.PubMedGoogle Scholar
  82. 82.
    Riley NE, Li J, McPhaul L, et al. Heat shock proteins are present in Mallory bodies (cytokeratin aggresomes) in human liver biopsies. Exp Molec Pathol. 2003;74:168–74.Google Scholar
  83. 83.
    Nan L, Wu Y, Bardag-Gorce F, et al. p62 is involved in the mechanism of Mallory body formation. Exp Mol Pathol. 2004;77:168–75.PubMedGoogle Scholar
  84. 84.
    Nan L, Wu Y, Bardag-Gorce F, et al. RNA interference of valosin-containing protein (VCP/p97) increases Mallory body formation. Exp Mol Pathol. 2005;78:1–9.PubMedGoogle Scholar
  85. 85.
    Cadrin M, Marceau N, French SW. Cytokeratin of apparent high molecular weight in livers from griseofulvin fed mice. J Hepatol. 1992;14:226–31.PubMedGoogle Scholar
  86. 86.
    Cadrin M, McFarlane-Anderson N, Aasheim N, et al. Differential phosphorylation of CK8 and CK18 by TPA in primary cultures of mouse hepatocytes. Cellular Signalling. 1992;4:715–22.PubMedGoogle Scholar
  87. 87.
    Cadrin M, Anderson NM, Aasheim LH, et al. Modifications in cytokeratin and actin in primary cultured liver cells derived from griseofulvin fed mice. Lab Invest. 1995;72:453–60.PubMedGoogle Scholar
  88. 88.
    Yuan QX, Nagao Y, Gaal K, et al. Mechanisms of Mallory Body formation induced by okadaic acid in drug primed mice. Exp Molec Pathol. 1998;65:87–103.Google Scholar
  89. 89.
    Nagao Y, Yuan Q-X, Wan Y-J, et al. Pathogenesis of Mallory body formation: studies using the drug-primed mouse model. Hepatol Res. 1998;13:15–24.Google Scholar
  90. 90.
    Kawahara H, Cadrin M, French SW. Ethanol-induced phosphorylation of cytokeratin in cultured hepatocytes. Life Sciences. 1990;47:859–63.PubMedGoogle Scholar
  91. 91.
    Bardag-Gorce F, Riley NE, Nan L, et al. The proteasome inhibitor, PS341, causes cytokeratin aggresome formation. Exp Molec Pathol. 2004;76:9–16.Google Scholar
  92. 92.
    Kachi K, Cadrin M, French SW. Synthesis of Mallory body intermediate filament and microfilament proteins in liver cell primary cultures: An electron microscopic autoradiography assay. Lab Invest. 1993;68:71–81.PubMedGoogle Scholar
  93. 93.
    Kawahara H, Marceau N, French SW. The excretory function in cultured hepatocytes containing Mallory bodies. Lab Invest. 1989;61:609–22.PubMedGoogle Scholar
  94. 94.
    Kachi K, Wong P, French SW. Molecular structural changes in Mallory body protein in human and mouse livers: an infrared spectroscopy study. Exp Molec Pathol. 1993;59:197–210.Google Scholar
  95. 95.
    French BA, van Leeuwen F, Riley NE, et al. Aggresome formation in liver cells in response to different toxic mechanisms. Role of the ubiquitin-proteasome pathway and the frameshift mutant of ubiquitin. Exp Molec Pathol. 2001;71:241–6.Google Scholar
  96. 96.
    Yuan QX, Nagao Y, French BA, et al. Dexamethasone enhances Mallory body formation in drug primed mouse liver. Exp Mol Path. 2000;69:202–10.Google Scholar
  97. 97.
    Yuan QX, Marceau N, French BA, et al. Mallory body induction in drug primed mouse liver. Hepatology. 1996;24:603–12.PubMedGoogle Scholar
  98. 98.
    Wu Y, Nan L, Bardag-Gorce F, et al. The role of laminin-integrin signaling in triggering (MB) formation: an in vivo and in vitro study. Exp Mol Pathol. 2005;79:1–8.PubMedGoogle Scholar
  99. 99.
    Nan L, Wu Y, Bardag-Gorce F, et al. The p105/50NF-κB pathway is essential for Mallory body formation. Exp Mol Pathol. 2005;78:198–206.PubMedGoogle Scholar
  100. 100.
    Nan L, Dedes J, French BA, et al. Mallory body (cytokeratin aggresomes) formation is prevented in vitro by p38 inhibitor. Exp Mol Pathol. 2006;80:228–40.PubMedGoogle Scholar
  101. 101.
    Leers MP, Kölgen W, Bjorklund V, et al. Immunocytochemical detection and mapping of a cytokeratin 18 neoepitope exposed during early apoptosis. J Pathol. 1999;187:567–72.PubMedGoogle Scholar
  102. 102.
    Amidi F, French BA, Chung D, et al. M30 and 4 HNE adducts are sequestered in different aggresomes in the same hepatocytes. Exp Mol Pathol. 2007;83:296–300.PubMedGoogle Scholar
  103. 103.
    Gonzalez-Quintela A, Abdulkader I, Campos J, et al. Serum levels of keratin-18 fragments [Tissue Polypeptide- specific antigen (TPS)] are correlated with hepatocyte apoptosis in alcoholic hepatitis. Dig Dis, Sci. 2009;54:648–53.Google Scholar
  104. 104.
    Gonzalez-Quinjela A, Mella C, Perez LF, Abdulkader I, et al. Increased serum TPS (tissue polypeptide specific antigen) in alcoholics. A possible marker of alcoholic hepatitis. Alcohol Clin Exp Res. 2000;24:1222–6.Google Scholar
  105. 105.
    Li J, Bardag-Gorce F, Dedes J, et al. S-adenosylmethionine prevents Mallory Denk body formation in drug-primed mice by inhibiting epigenetic memory. Hepatology. 2008;47:613–24.PubMedGoogle Scholar
  106. 106.
    Bardag-Gorce F, Oliva J, Villegas J, et al. Epigenetic mechanisms regulate Mallory Denk body formation in the livers of drug-primed mice. Exp Mol Pathol. 2008;94:113–21.Google Scholar
  107. 107.
    Bardag-Gorce F, Oliva J, French BA, et al. SAMe prevents the induction of immunoproteasome and preserves the 265 proteasome in the DDC-induced MDB mouse model. Exp Mol Pathol. 2010;88:353–362Google Scholar
  108. 108.
    French SW. Fibrosis in alcoholic cirrhosis in ethanol and the liver. In: Sherman DIN, Preedy VR, Watson RR, editors. Mechanisms and Management. London: Taylor and Francis Inc; 2002. p. 60–91.Google Scholar
  109. 109.
    Tsukamoto H, Tanner SJ, Ciofalo LM, et al. Ethanol-induced liver fibrosis in rats fed high fat diet. Hepatology. 1986;6:814–22.PubMedGoogle Scholar
  110. 110.
    French SW, Miyamoto K, Tsukamoto H. Ethanol-induced hepatic fibrosis in the rat: role of the amount of dietary fat. Alcohol Clin Exp Res. 1986;10:13S–9.PubMedGoogle Scholar
  111. 111.
    French SW, Miyamoto K, Wong K, et al. Role of the Ito cell in liver parenchymal fibrosis in rats fed alcohol and a high fat-low protein diet. Amer J Pathol. 1988;132:73–85.Google Scholar
  112. 112.
    Tsukamoto H, Matsuoka M, French SW. Experimental models of hepatic fibrosis: a review. Seminar Liver Dis. 1990;10:56–65.Google Scholar
  113. 113.
    Tsukamoto H, Gaal K, French SW. Insight into the pathogenesis of alcoholic liver necrosis and fibrosis: use of Tsukamoto-French rat model of alcoholic liver disease. Hepatology. 1990;12:599–608.PubMedGoogle Scholar
  114. 114.
    Xong S, She H, Zhang A-S, et al. Hepatic macrophage iron signaling in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol. 2008;295:G512–21.Google Scholar
  115. 115.
    Takahashi H, Wong K, Jui L, et al. Effect of dietary fat on Ito cell activation by chronic ethanol intake: a long term serial morphometric study on alcohol-fed and control rats. Alcoholism Clin Exp Res. 1991;15:1060–6.Google Scholar
  116. 116.
    Wang J-H, Batey RG, George J. Role of ethanol in the regulation of hepatic stellate cell function. World J Gastroenterol. 2006;12:6926–32.PubMedGoogle Scholar
  117. 117.
    Elinav E, Ali M, Bruck R, et al. Competitive inhibition of leptin signaling results in amelioration of liver fibrosis through modification of stellate cell function. Hepatology. 2009;49:278–86.PubMedGoogle Scholar
  118. 118.
    Ding X, Saxena NK, Lin S, et al. The roles of leptin and adiponectin. Am J Pathol. 2005;166:1655–69.PubMedGoogle Scholar
  119. 119.
    Sohail MA, Hashmi AZ, Hakim W, et al. Adenosine induces loss of actin stress fibers and inhibits contraction in hepatic stellate cells via Rho inhibition. Hepatology. 2009;49:185–94.PubMedGoogle Scholar
  120. 120.
    Miyamoto K, French SW. Hepatic adenosine in rats fed ethanol: effect of acute hyperoxia or hypoxia. Alcohol Clin Exp Res. 1988;12:512–5.PubMedGoogle Scholar
  121. 121.
    Li J, French BA, Fu P, et al. Liver necrosis induced by thyroid hormone administration in rats fed ethanol. Exp Molec Pathol. 2001;71:79–88.Google Scholar
  122. 122.
    Li J, French BA, Fu P, et al. Mechanism of alcohol cyclic pattern: Role of catecholamines. Am J Physiol Gastrointest Liver Physiol. 2003;285:G442–8.PubMedGoogle Scholar
  123. 123.
    Li J, French BA, Fu P, et al. Catecholamines are involved in the mechanism of the urinary alcohol level cycle in rats fed ethanol intragastrically at a constant rate. Life Sci. 2004;75:3043–51.PubMedGoogle Scholar
  124. 124.
    Purohit V, Brenner DA. Mechanisms of alcohol-induced hepatic fibrosis: a summary of the Ron Thurman Symposium. Hepatology. 2006;43:872–8.PubMedGoogle Scholar
  125. 125.
    Cook RT. Alcohol abuse, alcoholism and damage to the immune system-a review. Alcohol Clin Exp Res. 1998;22:1927–42.PubMedGoogle Scholar
  126. 126.
    Jeong W-I, Park O, Gao B. Abrogation of the antifibrotic effects of natural killer cells/interferon-γ(gamma) contributes to alcohol acceleration of liver fibrosis. Gastroenterology. 2008;124:248–58.Google Scholar
  127. 127.
    Nguyen VA, Gao B. Expression of interferon alfa signaling components in human alcoholic liver disease. Hepatology. 2002;35:425–32.PubMedGoogle Scholar
  128. 128.
    Chen W-X, Li Y-M, Yu C-H, et al. Quantitative analysis of transforming growth factor beta 1 mRNA in patients with alcoholic liver disease. World J Gastroenterol. 2002;8:379–81.PubMedGoogle Scholar
  129. 129.
    Jung Y, Brown KD, Wietek RP, et al. Accumulation of hedgehog-responsive progenitors parallel alcoholic liver disease severity in mice and humans. Gastroenterology. 2008;134:1532–43.PubMedGoogle Scholar
  130. 130.
    Dooley S, Hamzavi J, Clinician L, et al. Hepatocyte-specific Smad 7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage. Gastroenterology. 2008;135:642–59.PubMedGoogle Scholar
  131. 131.
    Godoy P, Hongsteer JG, Ilkavets I, et al. Extracelluar matrix modulates sensitivity of hepatocytes to fibroblastoid defifferentiation and transforming growth factor beta-induced apoptosis. Hepatology 2009 (E ahead of print).Google Scholar
  132. 132.
    Tsukamoto H. Epigenetic mechanism of stellate cell trans-differentiation. J Hepatol. 2007;46:352–3.PubMedGoogle Scholar
  133. 133.
    Stewart S, Jones D, Day CP. Alcoholic liver disease: new insights into mechanisms and preventive strategies. Trends Mol Med. 2001;7:408–13.PubMedGoogle Scholar
  134. 134.
    Lytton SD, Helander A, Zhang-Gouillon ZQ, et al. Autoantibodies against cytochrome P450s 2E1 and 3A in alcoholics. Molec Pharmacol. 1999;55:223–33.Google Scholar
  135. 135.
    Albano E, French S, Ingelman-Sundberg M. Cytochrome P450 2E1, hydroxethyl free radicals and immune reactions associated to alcoholic liver disease. Alcohol Clin Exp Res. 1998;22:739–42.Google Scholar
  136. 136.
    Guo J, Loke J, Zheng F, et al. Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology. 2009;49:960–8.PubMedGoogle Scholar
  137. 137.
    Febris C, Toniutto P, Falleti E, et al. MTHR C677T polymorphism and a risk of HCC in patients with liver cirrhosis: role of male gender and alcohol consumption. Alcohol Clin Exp Res. 2009;33:102–7.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Division of Anatomic Pathology, Department of PathologyHarbor UCLA Medical CenterTorranceUSA

Personalised recommendations